U.S. Markets closed

Nicolet Bankshares, Inc. (NCBS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
78.38-0.39 (-0.50%)
At close: 4:00PM EDT

78.38 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close78.77
Bid78.39 x 800
Ask78.47 x 1100
Day's Range76.91 - 78.48
52 Week Range45.33 - 86.25
Avg. Volume30,261
Market Cap782.852M
Beta (5Y Monthly)0.71
PE Ratio (TTM)13.75
EPS (TTM)5.70
Earnings DateApr 19, 2021 - Apr 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est87.20
  • MACKINAC ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MFNC and Encourages Investors to Contact the Firm

    MACKINAC ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MFNC and Encourages Investors to Contact the Firm

    NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Mackinac Financial Corporation (NASDAQ: MFNC) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Nicolet Bankshares, Inc. (NASDAQ: NCBS). Click here to learn more and participate in the action. On April 12, 2021, Mackinac announced that it had signed an agreement to be acquired by Nicolet for approximately $248 million. Pursuant to the merger agreement, Mackinac stockholders will receive 0.22 shares of Nicolet common stock and $4.64 in cash for each share of Mackinac common stock owned. The deal is scheduled to close in the third quarter of 2021. Bragar Eagel & Squire is concerned that Mackinac’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Mackinac’s stockholders. If you own shares of Mackinac and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Melissa Fortunato, Esq.Alexandra Raymond, Esq.investigations@bespc.comwww.bespc.com

  • SmarterAnalyst

    Wednesday’s Premarket: Here’s What You Need To Know Before The Market Opens

    US stock futures edged higher on Wednesday as investors await the start of the earnings season with a slew of corporate earnings expected to be announced today. Dow futures were 0.03% higher, S&P futures had gained 0.12%, and Nasdaq futures were up 0.4% at the time of writing. While Bed Bath & Beyond (BBBY), Goldman Sachs (GS), JP Morgan (JPM), Infosys (INFY), and Wells Fargo (WFC) are expected to release earnings before the opening bell, Green Tree Hospitality Group (GHG) and KLX Energy Services (KLXE) are expected to report after the market closes. Galectin (GALT) was the most actively traded and the biggest gainer in pre-market trading and was up by 29.3%. The pharma company said that the Journal for ImmunoTherapy of Cancer (JITC) had published clinical research indicating that Belapectin, the company’s Galectin-3 inhibitor, significantly enhanced responses to tumors in patients with metastatic melanoma. USA Technologies (USAT) was the biggest laggard falling 14.8% at the time of writing but this fall was unexplained as there was no fundamental news regarding the stock. In M&A news, Nicolet Bankshares (NCBS) has proposed the acquisition of Mackinac Financial Corporation that will result in NCBS assuming control of the bank. Under the terms of the agreement, Mackinac shareholders will be entitled to 0.22 shares of Nicolet’s common stock and will receive $4.64 for each Mackinac share. Nicolet National Bank’s CEO and President, Mike Daniels said, “Together, we will combine two organizations that understand the positive impact that a strong community bank can make. We look forward to becoming an integral part of the Upper Peninsula and Northern Michigan.” Bally’s Corporation (BALY) has also proposed the acquisition of Tropicana Las Vegas casino from Gaming and Leisure Properties (GLPI) at about $308 million. The company plans to lease out the land underlying the casino for a period of 50 years and pay $10.5 million as annual rent. Bally’s CEO and President George Papanier stated, “The Strip is visited by over 40 million players and guests per year, which we believe will significantly enhance Bally’s customer base and player database, as well as unlock marketing opportunities to leverage the iconic Bally’s brand. This expansion will also support the growth and development of our online and interactive business”. Public Storage (PSA) has acquired ezStorage in the United States for $1.8 billion. This acquisition is expected to close in May this year and is expected to be immediately accretive to funds from operations (FFO). Public Storage’s CEO Joe Russell said, “We are pleased to welcome the ezStorage customers to Public Storage’s industry-leading brand and platform. The acquisition is a direct reflection of Public Storage’s unique positioning for growth through acquisitions, development, redevelopment, and third-party management.” Meanwhile, Gilead Sciences’ (GILD) Trodelvy (sacituzumab govitecan-hziy) has received accelerated approval from the US Food and Drug Administration (FDA) for use in the treatment of adult patients who have urothelial cancer (UC), a type of bladder cancer. Gilead Sciences’ Chief Medical Officer, Merdad Parsey, MD, PhD said, “Today’s accelerated approval is thanks to the patients and healthcare professionals involved in the TROPHY study, and we appreciate their partnership. This achievement, coupled with last week’s full FDA approval in unresectable locally advanced or metastatic triple-negative breast cancer, underscores our commitment toward rapidly delivering Trodelvy to patients facing some of the most difficult-to-treat cancers.” SAP SE’s (SAP) posted its preliminary 1Q results with its cloud business recording the fastest growth in the past five years and revenue reaching €2.14 billion, up 7% year-on-year. The company also raised its financial outlook for FY21. SAP SE’s CEO Christian Klein said, “We are seeing very strong growth across all our applications. And we are just getting started. Our new offering ‘RISE with SAP’ is rapidly becoming a massive accelerator to our customers’ business transformations with our platform at the center. Together with our unique ecosystem of more than 22,000 partners and with a strong innovation pipeline for the year, we are well on track with our strategy to deliver robust cloud growth.” More recent articles from Smarter Analyst: FDA Approves New Drug Application For Axcella’s AXA1125; Shares Pop 10% Wall Street Roundup: Bullish & Bearish Calls Of The Day Score Media And Gaming's 2Q Revenue Misses Estimates; Shares Plunge 3% good natured Products Announces Preliminary Results For 1Q